Nebu-Flow

Nebu-Flow is a Glasgow-based medical technology company developing a next-generation nebuliser platform to fundamentally transform the delivery of inhaled medicines. Founded in 2019 as a spinout from the University of Glasgow by Dr Elijah Nazarzadeh and Professor Jonathan Cooper, the company was built around a breakthrough application of surface acoustic wave (SAW) technology to pulmonary drug delivery.

Nebu-Flow's technology improves the inhalable fraction of drugs by up to 60% compared to conventional devices, and can nebulise hard-to-deliver formulations including fragile biologics and RNA medicines. In 2024, Nebu-Flow raised £3.7 million backed by the Scottish Venture Fund, Ascension, and British Business Bank Investments.